60% Dividend Payout Soon: Pharma Stock Rallies 7% After Q4 Profit Reached Rs 85 Crore

Shares of Dr. Lal PathLabs Limited surged 7% on Monday after the company reported a staggering 52% jump in consolidated net profit, reaching Rs 85 crore for the quarter ended March 31, 2024, compared to Rs 56 crore in the same period last year.

This surge propelled the stock price to Rs 2509.90 on the BSE, marking a significant 6.92% increase, while on the NSE, it rose by 6.59% to Rs 2500.09. Investors responded positively to the impressive financial performance, reflecting confidence in the company's growth prospects.

"DLPL 4QFY24 results delivered a beat on our estimates, with revenue, EBITDA, and PAT outperforming by 5%, 8%, and 7%, respectively. Moreover, EBITDA margins also beat estimates by 90 bp. Overall revenue increased 11% YoY to INR5.4b, with sample volumes and patients growing 8.5%-3% YoY. The revenue per sample stood at INR 286 (+2.4% YoY). Sequentially, revenue grew by 1%, with sample volumes increasing by 2.7%, offset by a 1.4% decline in realisation per sample. Swasthfit revenue contribution increased to 24% in 4QFY24 (vs. 22%/20% in 4QFY23/3QFY24)," Centrum said in the report.

One of the key drivers of this performance was the substantial growth in revenue from operations, which increased by 11% to Rs 545 crore from Rs 491 crore in the corresponding quarter last year. This growth was attributed to various operational factors, including a 9% increase in the number of samples processed, totaling 19.1 million.

Additionally, revenue per sample grew by 2% to INR 286, and EBITDA per sample witnessed a significant 15% year-on-year increase to INR 76.

"Moreover, the gross margins are expected to be in the range of 78-80%. We have raised our earnings estimates for FY25/26 by 10% and 16%, respectively, on the back of: a) penetration into Tier 3 and 4 towns to drive volumes; b) Suburban becoming a dominant player in the Mumbai market; c) increasing contribution from Swasthfit; and d) reinvestment in growth. We value DLPL at a PE multiple of 42x at FY26 EPS of INR66 to arrive at our TP of INR2800. Maintain BUY," Centrum added.

The remarkable performance of Dr. Lal PathLabs' health and wellness platform, Swasthfit, was a noteworthy highlight of the quarter. In the fourth quarter of FY24, Swasthfit's sales increased by 24% year over year to INR 1.3 billion, accounting for 24% of overall revenue as opposed to 22% in the same time the previous year.

In line with its strong financial performance, Dr Lal PathLabs announced a final dividend of Rs 6 per equity share, amounting to 60% on a face value of Rs 10 each, for the financial year ended March 31, 2024. This move reflects the company's commitment to rewarding shareholders and creating long-term value.

"In FY24, Swasthfit revenue contribution increased ~200bp YoY to 24%, led by healthy traction. Going forward, DLPL plans to continue to increase Swasthfit contributions as it expands its reach. Moreover, investments in technology and digital infrastructure are yielding tangible results, enhancing DLPL's brand visibility and patient interactions," Centrum reports.

Moreover, the company's board approved the allotment of 2,500 equity shares under the Employee Stock Option Plan 2010 (ESOP 2010 Plan), leading to an increase in the paid-up equity share capital to Rs 83,48,03,520, divided into 8,34,80,352 equity shares.

The impressive quarterly results underscore Dr Lal PathLabs' resilience and ability to capitalise on growth opportunities in the diagnostics industry. With a focus on innovation, operational efficiency, and customer-centricity, the company is well-positioned for sustained growth and value creation in the future.

The investors remain optimistic about Dr Lal PathLabs' prospects, as evidenced by the surge in its share price. The company's strong operational performance and strategic initiatives bode well for its continued success and leadership in the healthcare sector.